vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and QUINSTREET, INC (QNST). Click either name above to swap in a different company.
QUINSTREET, INC is the larger business by last-quarter revenue ($287.8M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). QUINSTREET, INC runs the higher net margin — 17.4% vs -14.6%, a 32.0% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 1.9%). QUINSTREET, INC produced more free cash flow last quarter ($20.7M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 53.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
QUINSTREET, INCQNSTEarnings & Financial Report
QuinStreet, Inc. is a publicly traded online marketing company based in Foster City, California. The company helps generate web traffic for clients by acquiring popular domain names.
AXSM vs QNST — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $287.8M |
| Net Profit | $-28.6M | $50.2M |
| Gross Margin | — | 9.6% |
| Operating Margin | -13.8% | 0.4% |
| Net Margin | -14.6% | 17.4% |
| Revenue YoY | 65.0% | 1.9% |
| Net Profit YoY | 61.9% | 3342.5% |
| EPS (diluted) | $-0.55 | $0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $287.8M | ||
| Q3 25 | $171.0M | $285.9M | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | $269.8M | ||
| Q4 24 | $118.8M | $282.6M | ||
| Q3 24 | $104.8M | $279.2M | ||
| Q2 24 | $87.2M | $198.3M | ||
| Q1 24 | $75.0M | $168.6M |
| Q4 25 | $-28.6M | $50.2M | ||
| Q3 25 | $-47.2M | $4.5M | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | $4.4M | ||
| Q4 24 | $-74.9M | $-1.5M | ||
| Q3 24 | $-64.6M | $-1.4M | ||
| Q2 24 | $-79.3M | $-2.2M | ||
| Q1 24 | $-68.4M | $-7.0M |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | 9.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.8% | ||
| Q1 24 | — | 8.5% |
| Q4 25 | -13.8% | 0.4% | ||
| Q3 25 | -27.0% | 1.7% | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | 1.8% | ||
| Q4 24 | -61.1% | -0.5% | ||
| Q3 24 | -59.8% | -0.4% | ||
| Q2 24 | -89.5% | -0.7% | ||
| Q1 24 | -89.7% | -3.2% |
| Q4 25 | -14.6% | 17.4% | ||
| Q3 25 | -27.6% | 1.6% | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | 1.6% | ||
| Q4 24 | -63.1% | -0.5% | ||
| Q3 24 | -61.7% | -0.5% | ||
| Q2 24 | -91.0% | -1.1% | ||
| Q1 24 | -91.1% | -4.2% |
| Q4 25 | $-0.55 | $0.87 | ||
| Q3 25 | $-0.94 | $0.08 | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | $0.08 | ||
| Q4 24 | $-1.54 | $-0.03 | ||
| Q3 24 | $-1.34 | $-0.02 | ||
| Q2 24 | $-1.67 | $-0.04 | ||
| Q1 24 | $-1.44 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $107.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $294.4M |
| Total Assets | $689.8M | $493.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $107.0M | ||
| Q3 25 | $325.3M | $101.3M | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | $81.8M | ||
| Q4 24 | $315.4M | $57.8M | ||
| Q3 24 | $327.3M | $25.0M | ||
| Q2 24 | $315.7M | $50.5M | ||
| Q1 24 | $331.4M | $39.6M |
| Q4 25 | $88.3M | $294.4M | ||
| Q3 25 | $73.7M | $246.7M | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | $235.5M | ||
| Q4 24 | $57.0M | $224.3M | ||
| Q3 24 | $92.9M | $219.8M | ||
| Q2 24 | $102.9M | $216.8M | ||
| Q1 24 | $144.0M | $215.0M |
| Q4 25 | $689.8M | $493.0M | ||
| Q3 25 | $669.3M | $442.6M | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | $417.2M | ||
| Q4 24 | $568.5M | $409.6M | ||
| Q3 24 | $561.5M | $401.2M | ||
| Q2 24 | $548.2M | $368.5M | ||
| Q1 24 | $545.7M | $349.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $21.6M |
| Free Cash FlowOCF − Capex | $-18.7M | $20.7M |
| FCF MarginFCF / Revenue | -9.6% | 7.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 0.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $106.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $21.6M | ||
| Q3 25 | $1.0M | $19.6M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.4M | $30.1M | ||
| Q4 24 | $-26.2M | $38.7M | ||
| Q3 24 | $-18.6M | $-13.7M | ||
| Q2 24 | $-30.1M | $16.6M | ||
| Q1 24 | $-53.5M | $4.1M |
| Q4 25 | $-18.7M | $20.7M | ||
| Q3 25 | $988.0K | $18.4M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | $29.5M | ||
| Q4 24 | $-26.2M | $38.2M | ||
| Q3 24 | $-18.7M | $-14.1M | ||
| Q2 24 | $-30.2M | $15.4M | ||
| Q1 24 | $-53.6M | $2.9M |
| Q4 25 | -9.6% | 7.2% | ||
| Q3 25 | 0.6% | 6.4% | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | 10.9% | ||
| Q4 24 | -22.1% | 13.5% | ||
| Q3 24 | -17.9% | -5.1% | ||
| Q2 24 | -34.6% | 7.8% | ||
| Q1 24 | -71.4% | 1.7% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.2% | ||
| Q2 24 | 0.1% | 0.6% | ||
| Q1 24 | 0.1% | 0.7% |
| Q4 25 | — | 0.43× | ||
| Q3 25 | — | 4.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 6.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
QNST
| Financial Service | $216.8M | 75% |
| Home Services And Other Revenue | $71.0M | 25% |
